# 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

> **NCT01101841** · PHASE3 · COMPLETED · sponsor: **Noven Therapeutics** · enrollment: 570 (actual)

## Conditions studied

- Hot Flashes

## Interventions

- **DRUG:** Brisdelle (paroxetine mesylate)
- **DRUG:** Placebo capsules

## Key facts

- **NCT ID:** NCT01101841
- **Lead sponsor:** Noven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-11
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101841, "24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01101841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*